APX 3330
Alternative Names: APX-3330; E-3330Latest Information Update: 10 May 2024
At a glance
- Originator Eisai Co Ltd
- Developer Apexian Pharmaceuticals; Ocuphire Pharma
- Class Anti-inflammatories; Antineoplastics; Antivirals; Eye disorder therapies; Hepatoprotectants; Neuroprotectants; Quinones; Small molecules
- Mechanism of Action Angiogenesis inhibitors; APEX1 protein inhibitors; DNA apurinic apyrimidinic site lyase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Diabetic retinopathy; Hepatitis B; Hepatitis C; Liver cirrhosis
- Phase I Solid tumours
- Preclinical Inflammatory bowel diseases; Pancreatic cancer
- Discontinued Haematological malignancies; Liver disorders; Peripheral nervous system diseases
Most Recent Events
- 06 May 2024 Updated adverse events data from the phase II ZETA-1 trial in Diabetic retinopathy released by Ocuphire Pharma
- 16 Apr 2024 Discontinued - Phase-I for Peripheral nervous system diseases (Chemotherapy-induced) in USA (PO) before April 2024 (Apexian Pharmaceuticals pipeline, April 2024)
- 29 Feb 2024 Ocuphire Pharma files special protocol assessment (SPA) to US FDA for phase-III trial for Diabetic retinopathy